Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
Rhea-AI Summary
Atea Pharmaceuticals (Nasdaq: AVIR) will host a live conference call and audio webcast on May 12, 2026 at 4:30 p.m. ET to report first quarter results for the period ended March 31, 2026 and provide a business update. The webcast will be archived on the company's investor site approximately two hours after the call and remain available for at least 90 days.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – AVIR
On the day this news was published, AVIR declined 1.75%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AVIR gained 2.15% with modestly above-average volume, while scanner-flagged peers like NMRA and LXEO showed upside momentum. Broader peer moves appear mixed rather than tightly correlated with AVIR.
Previous Conferences,earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Earnings call notice | Neutral | +1.3% | Scheduled Q4 and full-year 2025 results call and business update. |
| Nov 05 | Earnings call notice | Neutral | +0.9% | Announced Q3 2025 results call and business update timing. |
| Jul 31 | Earnings call notice | Neutral | -0.8% | Set date and access details for Q2 2025 results call. |
| Feb 27 | Earnings call notice | Neutral | -3.2% | Scheduled Q4 and full-year 2024 results and update call. |
| Oct 31 | Earnings call notice | Neutral | -1.2% | Announced Q3 2024 results call and webcast logistics. |
Prior conference/earnings call announcements for AVIR have typically produced small stock moves, with an average 24h move of -0.59% around similar scheduling releases.
Recent AVIR news highlighted late-stage HCV development, HEV pipeline progress, and regular quarterly reporting. Key items included Q4 and full-year 2025 results with a business update on Mar 5, 2026, strategic and pipeline priorities shared in early 2026, and repeated scheduling of conference calls to discuss financials and updates. Within this pattern, today’s notice of a May 12, 2026 Q1 call fits the established cadence of communications around earnings and clinical strategy.
Historical Comparison
In the past, AVIR issued 5 similar conference/earnings call notices, with an average 24h move of -0.59%, indicating typically modest reactions to this type of scheduling update.
Conference and earnings call notices have consistently preceded detailed financial reports and business updates as AVIR advanced its late-stage HCV and emerging HEV programs.
Market Pulse Summary
This announcement sets the timing for AVIR’s Q1 2026 results and business update on May 12, 2026. It follows a consistent pattern of quarterly conference calls that accompany financial disclosures and late-stage HCV and HEV pipeline updates. Investors may focus on how upcoming commentary compares with prior milestones, including Phase 3 HCV progress and planned HEV clinical initiation, as well as any changes to cash usage or development timelines.
AI-generated analysis. Not financial advice.
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Tuesday, May 12, 2026, at 4:30 p.m. ET to report financial results for the first quarter ended March 31, 2026, and to provide a business update.
To access the live conference call, participants may register here. The live audio webcast of the call will be available under “Events and Presentations” in the Investor Relations section of the Atea Pharmaceuticals website at ir.ateapharma.com. To participate via telephone, please dial 1-877-407-0779 (U.S.) or 1-201-389-0914 (International) and use conference ID number 13759581. An archive of the audio webcast will be available on Atea’s website approximately two hours after the conference call and will remain available for at least 90 days following the event.
About Atea Pharmaceuticals
Atea is a late-stage clinical biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Atea’s Phase 3 program is evaluating the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, to treat HCV. Atea anticipates advancing AT-587, a nucleotide analog, for the treatment of HEV into Phase 1 after completion of investigational new drug / clinical trial application enabling studies. For more information, please visit www.ateapharma.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the Company’s plans relating to the date and time of the anticipated conference call and audio webcast. When used herein, words including “may,” “will,” “anticipates,” “plans,” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, the important factors discussed and updated from time to time under the caption “Risk Factors” in the reports the Company files with the SEC, including annual reports on Form10-K, quarterly reports on Form10-Q, current reports on Form 8-K and other filings each of which are accessible on the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. All forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. Forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Contacts
Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
